{
  "docId": "019de072-e6c6-771e-b24a-5adaac3cef4b",
  "docSlug": "1c626f0801e0e9ad1e805f8e0140c291",
  "documentTitle": "Alkermes | Results Presentation Deck | 26 slides",
  "authorId": "alkermes",
  "authorName": "Alkermes",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-06-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 19,
  "pageCount": 26,
  "prevPage": 18,
  "nextPage": 20,
  "slideType": "kpi_overview",
  "function": "analyze_data",
  "density": "dense",
  "nDataPoints": 56,
  "notes": "Diverging bar chart showing Grade 1-2 and Grade 3-4 events for two cohorts.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de072-e6c6-771e-b24a-5adaac3cef4b/19",
  "deckHref": "/decks/019de072-e6c6-771e-b24a-5adaac3cef4b",
  "deckJsonHref": "/decks/019de072-e6c6-771e-b24a-5adaac3cef4b.json",
  "deckAnchorHref": "/decks/019de072-e6c6-771e-b24a-5adaac3cef4b#slide-19",
  "components": [
    {
      "bbox": {
        "h": 0.6,
        "w": 0.55,
        "x": 0.05,
        "y": 0.25
      },
      "kind": "chart",
      "text": "Diverging bar chart of TRAEs",
      "attrs": null,
      "subkind": "bar-stacked",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9d3bf834-010e-41d7-aaf4-85fe7bde5097",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.35,
        "x": 0.62,
        "y": 0.23
      },
      "kind": "list",
      "text": "AE profile consistent with nemvaleukin mechanism of action; Monotherapy safety profile was similar to combination safety profile with no additive toxicity observed; Most frequently observed grade 3/4 TRAE: neutropenia; TRAEs leading to discontinuation: 3% (monotherapy), 4% (combination); No event of capillary leak syndrome reported to date in ARTISTRY-1",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "71fd170a-0ab0-41cf-9add-6f9ed17e4dca",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.5,
        "x": 0.03,
        "y": 0.88
      },
      "kind": "source-note",
      "text": "Part C includes patients who received nemvaleukin at 1, 3, or 6 µg/kg IV in combination with pembrolizumab 200 mg IV. Includes neutropenia and decreased neutrophil count. AE, adverse event; TRAEs, treatment-related AEs.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3b67cfc9-7e00-4c43-8555-994dbc20cc84",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.5,
        "x": 0.05,
        "y": 0.08
      },
      "kind": "title",
      "text": "ARTISTRY-1: Overall Safety Summary",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "14d19610-be67-4206-a599-4abee599bab7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.5,
        "x": 0.05,
        "y": 0.13
      },
      "kind": "title",
      "text": "Dose Expansion: Monotherapy and Combination Therapy",
      "attrs": null,
      "subkind": "subtitle",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "69ec4c59-73fc-443b-9afa-564fe093640a",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 20,
      "from": 9,
      "beatId": "04379692-f7a3-428c-883b-94305cddc327",
      "arcName": "The Consultant's Gambit",
      "arcSlug": "consultants-gambit",
      "beatName": "Evidence & Proof",
      "beatSlug": "consultants-gambit-evidence-proof",
      "evidence": "Slides 9-20 provide results from clinical trials.",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [
    {
      "to": 20,
      "from": 15,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "de462ce0-7910-4bf9-8add-416bb065dc4b",
      "evidence": "Slides 15-20 discuss the combination therapy.",
      "position": 1,
      "objective": "How does Nemvaleukin Alfa work in combination with Pembrolizumab?",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.7,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}